Document is current
Any future updates will be listed below
-
Authors
Salmon-Divon, Mali
Meyuchas, Refael https://orcid.org/0009-0007-6744-1969
Shpilberg, Ofer
Okon, Elimelech
Benhamida, Jamal
Yabe, Mariko
Petrova-Drus, Kseniya
Zvida-Bloch, Tal
Basood, May
Mazor, Roei
Durham, Benjamin H.
Haroche, Julien
Abdel-Wahab, Omar
Diamond, Eli L. https://orcid.org/0000-0001-5456-5961
Hershkovitz-Rokah, Oshrat https://orcid.org/0000-0003-4685-0679
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (R01 CA283364, HL128239, R01 CA242020)
Cycle for survival, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Frame Family Fund, Joy Family West Foundation, Applebaum Foundation
- License Information
-
More Information
Article History
Received: 7 September 2024
Revised: 26 October 2024
Accepted: 31 October 2024
First Online: 8 November 2024
Competing interests
: ELD discloses unpaid editorial support from Pfizer Inc. and serves on an advisory board for Day One Biotherapeutics, SpringWorks Therapeutics and Opna Bio, all outside the submitted work. OA-W is a founder and scientific advisor of Codify Therapeutics, holds equity in this company, and receives research funding from this company. OA-W has served as a consultant for Foundation Medicine Inc., Merck, Prelude Therapeutics, Amphista Therapeutics, MagnetBio, and Janssen, and is on the Scientific Advisory Board of Envisagenics Inc., Harmonic Discovery Inc., and Pfizer Boulder; OA-W has received prior research funding from H3B Biomedicine, Nurix Therapeutics, Minovia Therapeutics, and LOXO Oncology unrelated to the current manuscript. MY serves as a consultant for Bristol Myers Squibb and Janssen Pharmaceuticals, both of which are unrelated to the current manuscript. The remaining authors declare no competing interests.
: The authors confirm that all methods were performed in accordance with the Declaration of Helsinki. This study was approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center (MSK Protocols #12-245 and #16-1604), Assuta Medical Center (#2015097), and Comité de Protection des Personnes Ile de France III (#2011-A00447-34). All participants provided informed consent.
